poisar

Stocks · News reference

QuinStreet Sees Q1 Sales $370.000M-$380.000M vs $355.568M Est

Benzinga Newsdesk

QuinStreet (NASDAQ:QNST) sees Q1 sales of $370.000 million-$380.000 million vs $355.568 million analyst estimate.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

QNST
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Unknown

    QUINT Brings Concentrated Exosome Technology Home With Monthly Skin and Scalp Protocols

    QUINT, the direct-to-consumer beauty biotechnology brand, has introduced Q.FACE and Q.SCALP—structured monthly microneedling protocols that combine 25 billion exosomes with precision microneedling applicators. The systems are designed to simplify at-home skincare and scalp treatments by offering standardized dosing, guided application, and a three-month protocol, positioning exosomes as an intentional treatment rather than a daily cosmetic ingredient.

    QNST
  2. Jack Delaney

    QuinStreet CFO Gregory Wong Sells 11,704 Shares

    QuinStreet CFO Gregory Wong sold 11,704 shares worth approximately $239,230 on August 18, 2026, representing 2% of his direct holdings. Wong retains 481,786 shares valued at $10 million. The article characterizes this as routine profit-taking given the stock's strong 41% performance over the past 12 months and management's positive fiscal 2027 revenue growth projections of 16-31%.

    QNST